How should I use this medicine?

LIBTAYO is administered intravenously at a recommended dose of 350 mg every 3 weeks until disease progression or unacceptable toxicity.

Dosage of LIBTAYO

The recommended dosage of LIBTAYO is 350 mg administered as an intravenous infusion over 30 minutes every 3 weeks. Treatment continues until either disease progression or the occurrence of unacceptable toxicity. There is no recommended dose reduction; however, dosage modifications may be required for managing adverse reactions. No additional dosing regimen has been provided for different patient subgroups such as pediatric or geriatric populations. The specific preparation and administration procedures, including necessary precautions for intravenous administration, are also outlined but not specified in the description.

LIBTAYO(Lebrikizumab)
LIBTAYO is indicated for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma.
RELATED ARTICLES
/ 0
0 in total
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved